Possible Anandamide and Palmitoylethanolamide involvement in human stroke

详细信息    查看全文

• 作者：Marcello Naccarato (1)
  Daniela Pizzuti (2)
  Stefania Petrosino (3)
  Marco Simonetto (1)
  Laura Ferigo (1)
  Fabio Chiodo Grandi (1)
  Gilberto Pizzolato (1)
  Vincenzo Di Marzo (3)
  
• 刊名：Lipids in Health and Disease
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：9
• 期：1
• 全文大小：769KB
• 参考文献：1. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, Leon A: The ALIamide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. / Proc Natl Acad Sci USA 1996, 93:3984鈥?989. CrossRef
  2. Lombardi G, Miglio G, Varsaldi F, Minassi A, Appendino G: Oxyhomologation of the amide bond potentiates neuroprotective effects of the endolipid N-palmitoylethanolamine. / J Pharmacol Exp Ther 2007, 320:599鈥?06. CrossRef
  3. Schomacher M, M眉ller HD, Sommer C, Schwab S, Sch盲bitz WR: Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. / Brain Res 2008, 1240:213鈥?20. CrossRef
  4. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A: Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. / Proc Natl Acad Sci USA 1995, 92:3376鈥?380. CrossRef
  5. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D: The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. / Mol Pharmacol 2005, 67:15鈥?9. CrossRef
  6. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G: The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. / Pain 2008, 139:541鈥?50. CrossRef
  7. Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA: Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. / Mol Pharmacol 2006, 69:691鈥?96.
  8. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ: Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. / Neuroscience 2004, 129:743鈥?50. CrossRef
  9. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HHO: Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? / J Neurochem 2004, 88:1159鈥?167. CrossRef
  10. Jin K, Mao XO, Goldsmith PC, Greenberg DA: CB1 cannabinoid receptor induction in experimental stroke. / Ann Neurol 2000, 48:257鈥?61. CrossRef
  11. Amantea D, Spagnuolo P, Bari M, Fezza F, Mazzei C, Tassorelli C, Morrone LA, Corasaniti MT, Maccarrone M, Bagetta G: Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol. / FEBS J 2007, 274:4464鈥?475. CrossRef
  12. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA: Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. / J Neurosci 2002, 22:9771鈥?775.
  13. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. / J Neurosci 1999, 19:2987鈥?995.
  14. Pegorini S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, Sala M: Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. / Br J Pharmacol 2005, 144:727鈥?35. CrossRef
  15. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF: Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. / Neuroscience 2008, 152:753鈥?60. CrossRef
  16. Ashton JC, Rahman RMA, Nair SM, Sutherland BA, Glass M, Appleton I: Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. / Neurosci Lett 2007, 412:114鈥?17. CrossRef
  17. Saleh A, Schroeter M, Ringelstein A, Hartung HP, Siebler M, Modder U, Jander S: Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke. / Stroke 2007, 38:2733鈥?737. CrossRef
  18. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF: Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. / J Cereb Blood Flow Metab 2007, 27:1387鈥?396. CrossRef
  19. Sch盲bitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S, Piomelli D: Release of fatty acid amides in a patient with hemispheric stroke. / Stroke 2002, 33:2112鈥?114. CrossRef
  20. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M: Measurements of acute cerebral infarction: a clinical examination scale. / Stroke 1989, 20:864鈥?70.
  21. R枚d茅n-J眉llig 脜, Gustafsson C, Fugl-Meyer A: Validation of four scales for the acute stage of stroke. / J Internal Med 1994, 236:125鈥?36. CrossRef
  22. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V: Endocannabinoid signalling in the blood of patients with schizophrenia. / Lipids Health Dis 2003, 2:5. CrossRef
  23. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V: Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. / Neuropsychopharmacology 2005, 30:1216鈥?221. CrossRef
  24. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P, Schon MR, Jordan J, Stumvoll M: Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. / Diabetes 2006, 55:3053鈥?060. CrossRef
  25. Zolese G, Bacchetti T, Ambrosini A, Wozniak M, Bertoli E, Ferretti G: Increased plasma concentrations of Palmitoylethanolamide, an endogenous fatty acid amide, affect oxidative damage of human low-density lipoproteins: An in vitro study. / Atherosclerosis 2005, 182:47鈥?5. CrossRef
  26. Di Marzo V: Targeting the endocannabinoid system: to enhance or reduce? / Nat Rev Drug Discov 2008, 7:438鈥?55. CrossRef
  27. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, De Chiara V, Battistini L, Bernardi G, Bernardini S, Martino G, Maccarrone M: The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. / Brain 2007, 130:2543鈥?553. CrossRef
  28. Battista N, Bari M, Tarditi A, Mariotti C, Bachoud-L茅vi AC, Zuccato C, Finazzi-Agr貌 A, Genitrini S, Peschanski M, Di Donato S, Cattaneo E, Maccarrone M: Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. / Neurobiol Dis 2007, 27:108鈥?16. CrossRef
  29. Cupini LM, Bari M, Battista N, Argir貌 G, Finazzi-Agr貌 A, Calabresi P, Maccarrone M: Biochemical changes in endocannabinoid system are espresse in platelets of female but not male migraineurs. / Cephalalgia 2006, 26:277鈥?81. CrossRef
  30. Rossi C, Pini LA, Cupini ML, Calabresi P, Sarchielli P: Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. / Eur J Clin Pharmacol 2008, 64:1鈥?. CrossRef
  31. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ: Serum endocannabinoid contentis altered in females with depressive disorders: a preliminary report. / Pharmacopsychiatry 2008, 41:48鈥?3. CrossRef
  32. Centonze D, Battistini L, Maccarrone M: The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. / Curr Pharm Des 2008, 14:2370鈥?442. CrossRef
  33. Pellegrini-Giampietro DE, Mannaioni G, Bagetta G: Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death. / FEBS Journal 2009, 276:2鈥?2. CrossRef
  34. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, Gasperi V, Prosperetti C, Bernardi G, Finazzi-Agr貌 A, Cravatt BF, Centonze D: Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. / Nat Neurosci 2008, 11:152鈥?59. CrossRef
  35. Re G, Barbero R, Miolo A, Di Marzo V: Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. / Vet J 2007, 173:21鈥?0. CrossRef
  36. Mechoulam R, Shohami E: Endocannabinoids and traumatic brain injury. / Mol Neurobiol 2007, 36:68鈥?4. CrossRef
  
• 作者单位：Marcello Naccarato (1)
  Daniela Pizzuti (2)
  Stefania Petrosino (3)
  Marco Simonetto (1)
  Laura Ferigo (1)
  Fabio Chiodo Grandi (1)
  Gilberto Pizzolato (1)
  Vincenzo Di Marzo (3)
  
  1. Department of Medical, Technological and Translational Sciences, Neurology Unit, University of Trieste, Strada di Fiume 447, 34100, Trieste, (TS), Italy
  2. Department of Surgical and Gastroenterological Sciences, University of Padova, Via Giustiniani 5, Padova, (PD), Italy
  3. Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council, Via Campi Flegrei 34, Pozzuoli, (NA), Italy
  

文摘

Background Endocannabinoids (eCBs) are ubiquitous lipid mediators that act on specific (CB1, CB2) and non-specific (TRPV1, PPAR) receptors. Despite many experimental animal studies proved eCB involvement in the pathogenesis of stroke, such evidence is still lacking in human patients. Our aim was to determine eCB peripheral levels in acute stroke patients and evaluate their relationship with clinical disability and stroke volume. Methods A cohort of ten patients with a first acute (within six hours since symptoms onset) ischemic stroke and a group of eight age- and sex-matched normal subjects were included. Groups were also matched for metabolic profile. All subjects underwent a blood sample collection for anandamide (AEA), 2-arachidonoylglycerol (2-AG) and palmitoylethanolamide (PEA) measurement; blood sampling was repeated in patients on admission (T0), at 6 (T1) and 18 hours (T2) thereafter. Patients neurological impairment was assessed using NIHSS and Fugl-Meyer Scale arm subitem (FMSa); stroke volume was determined on 48 h follow-up brain CT scans. Blood samples were analyzed by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. Results 1)T0 AEA levels were significantly higher in stroke patients compared to controls. 2)A significant inverse correlation between T0 AEA levels and FMSa score was found. Moreover a positive correlation between T0 AEA levels and stroke volume were found in stroke patients. T0 PEA levels in stroke patients were not significantly different from the control group, but showed a significant correlation with the NIHSS scores. T0 2-AG levels were lower in stroke patients compared to controls, but such difference did not reach the significance threshold. Conclusions This is the first demonstration of elevated peripheral AEA levels in acute stroke patients. In agreement with previous murine studies, we found a significant relationship between AEA or PEA levels and neurological involvement, such that the greater the neurological impairment, the higher were these levels.